Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

v2.4.0.6
Share-based compensation
 3 Months Ended
Oct. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 3 – Share-based compensation


The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:


 

 

 

 

 

 

 

 

 

 

Three months ended
October 31,

 

 

 

2012

 

2011

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

2

 

$

2

 

Research and development

 

 

1

 

 

3

 

Selling, general and administrative

 

 

139

 

 

208

 

 

 

   

 

   

 

 

 

$

142

 

$

213

 

 

 

   

 

   

 


No excess tax benefits were recognized during the three month periods ended October 31, 2012 and 2011.


Stock option plans


A summary of the activity relating to the Company’s stock option plans for the three month period ended October 31, 2012 is as follows:


 

 

 

 

 

 

 

 

 

 

 

 

 

Options

 

Weighted
Average
Exercise Price

 

Aggregate
Intrinsic Value

 

 

 

 

 

 

 

 

 

Outstanding at July 31, 2012

 

 

736,490

 

$

14.50

 

$

—

 

 

 

 

 

 

 

 

 

   

 

Exercised

 

 

—

 

 

—

 

 

 

 

Cancelled

 

 

(50,638

)

$

11.25

 

 

 

 

 

 

   

 

 

 

 

 

 

 

Outstanding and exercisable at end of period

 

 

685,852

 

$

14.74

 

$

—

 

 

 

   

 

 

 

 

   

 


As of October 31, 2012, there were no unvested stock options.


Restricted Stock Awards


A summary of the activity pursuant to the Company’s restricted stock awards for the three months ended October 31, 2012 is as follows:


 

 

 

 

 

 

 

 

 

 

Awards

 

Weighted
Average
Award Price

 

 

 

 

 

 

 

Unvested at July 31, 2012

 

 

257,583

 

$

3.58

 

Awarded

 

 

30,000

 

$

1.52

 

Vested

 

 

(500

)

$

(3.93

)

Forfeited

 

 

(3,292

)

$

(5.13

)

 

 

   

 

   

 

Unvested at end of period

 

 

283,791

 

$

3.34

 

 

 

   

 

   

 


The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of October 31, 2012, there was approximately $0.5 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately one year.


The total number of shares available for grant as equity awards is approximately 2,658,000 as of October 31, 2012.